MEDDAY PHARMACEUTICALS SA: Strengthens its Board with Two

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MEDDAY PHARMACEUTICALS SA: Strengthens its Board with Two Senior Non-Executive Directors

PARIS, Sept. 29, 2016 (GLOBE NEWSWIRE) -- MedDay, a biotechnology company focused on the treatment of nervous system disorders, is today pleased to announce the appointment of Janet Vergis and George M. Garibaldi M.D. as independent Non-Executive Directors to its Board, with immediate effect.

Janet Vergis has more than 25 years' experience in the healthcare industry with a strong track record with growing businesses. She currently serves as an Executive Advisor to private equity firms and was most recently Chief Executive Officer of OraPharma, Inc. where she led the successful turnaround and subsequent sale of the company. Prior to these roles, Ms. Vergis managed a $6 billion portfolio at Johnson & Johnson as President of Janssen Pharmaceutica, McNeil Pediatrics, and Ortho-McNeill Neurologics. During her five years as President she led over 1,700 employees to deliver double-digit increases in revenue and profit across the three companies. Vergis currently serves on the Board of Directors for Church and Dwight Co., Inc. and Impax Laboratories, Inc., is Chairman of the Biotech Advisory Board and a Member of The Dean's Advisory Counsel for The Eberly College of Science at The Pennsylvania State University.

Dr George M. Garibaldi has more than 25 years' global pharmaceutical and academic experience in early to late-stage drug development specialising in small and large molecules, sporadic and rare diseases, leading to multiple product approvals in the area of neurology and psychiatry. Most recently, Dr Garibaldi was Vice President of Neuroscience and Product Development, at Hoffmann-La Roche AG, where he successfully designed, implemented and executed three Phase III programs in Primary and Relapsing Remitting multiple sclerosis (Ocrelizumab), schizophrenia and Alzheimer's disease. Previously Dr Garibaldi worked for Janssen Pharmaceuticals, LLC as Therapy Area Lead, Neuroscience, and for Novartis as Executive Director, specialising in nervous system clinical research and development. He is the Founder and previous President of the International Society for CNS Clinical Trials and Methodology (ISTCM) and is currently the Chairman of the International Society of CNS Drug Development (ISCDD). In these roles, he promotes advancing trial methodology and paving the roads for novel approaches to enhancing research outcomes in diseases of the nervous system. He is a Member of the Collegium Internationale Neuro-psychopharmacologicum (CINP) and of the American Academy of Child and Adolescent psychiatry.  

Commenting on the appointments Catherine Moukheibir, Chairman of the board, said: "I am delighted to welcome George and Janet to MedDay, both of whom are world leaders in their respective fields and will bring a wealth of knowledge and experience to MedDay's Board that will strengthen our existing team as we continue to move forward with our late-stage product development activity and strategic goals."

Ms Janet Vergis commented : "I look forward to joining MedDay to help with the next stages of its growth. I strongly believe that MD1003 has the potential to become a breakthrough therapy in progressive Multiple Sclerosis and meets a significant need in the marketplace."

Dr. George M. Garibaldi commented: "I am excited to be joining the Board of MedDay at this important time in the Company's development as it moves forward with its lead candidate in progressive multiple sclerosis. I believe MedDay, with its innovative research approaches, has uncovered an enormous potential to make a significant impact on the lives of patients with progressive multiple sclerosis, a truly debilitating condition. MedDay's product pipeline and its research platform, SPECMET, have great potential in changing the landscape for future therapy of neurological diseases."

- Ends -

About MedDay MedDay is a privately held biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer); and Guillaume Brion, MD (Chief Operating Officer). The Company's most advanced pipeline candidate is MD1003 for the treatment of primary and secondary progressive multiple sclerosis. MedDay is well funded by investors including Sofinnova Partners, InnoBio, Edmond de Rothschild Investment Partners and Bpifrance Large Venture. For more information, please see: www.medday-pharma.com . Follow us on Twitter @MedDay Pharma

For more information, please contact:

MedDay Pharmaceuticals Email: contact@medday-pharma.com

Consilium Strategic Communications Mary-Jane Elliott, Jonathan Birt, Laura Thornton, Melissa Gardiner Tel: +44 (0)20 3709 5700 Email: medday@consilium-comms.co m

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
San Bernardino Teamsters Back Their Historic Contract

Updated Category News Views 94

A 90% vote does not whisper; it rattles the filing cabinets. More than 12,000 San Bernardino County members of Teamsters Local 1932 have ratified a new labor agreement with over 90% approval, according to the union’s November 20 announcement. In a public-sector negotiation, that kind of margin matters because it tells management the workforce is not merely accepting a...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 100

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 144

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 92

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Re-Decking or Rebuilding Starts Below the Deck Boards

Updated Category News Views 47

A weathered deck can fool the eye in both directions: ugly boards may sit atop solid framing, while a tidy surface can hide trouble where nobody bothers to look. That is the useful, sober point in Dawn Walsh's guidance for Knoxville homeowners. The decision is not really about whether the top boards look tired. It is about whether the bones underneath still deserve...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover Sustainability LIVE: The Middle East Summit 2026 Insights

Updated Category News Views 218

BizClik Announces Sustainability LIVE: The Middle East Summit BizClik, the renowned global B2B media company behind the well-known Sustainability Magazine, is setting the stage for an ambitious event called Sustainability LIVE: The Middle East Summit. This summit is scheduled to take place virtually from 3-4 February 2026, providing a unique opportunity for leaders in...

Continue Reading
Bureau Veritas Ceases Discussions on Business Merger Plans

Updated Category News Views 137

Bureau Veritas Concludes Discussions on Future Collaboration In a recent declaration, Bureau Veritas disclosed that discussions surrounding a potential merger with SGS have ceased. The talks, which commenced with optimism about the potential synergies between the two leading firms in the Testing, Inspection, and Certification (TIC) industry, did not reach a conclusive...

Continue Reading
Bernstein's Insights: Why Royal Caribbean Outshines Carnival

Updated Category News Views 295

Bernstein Analyzes the Cruise Industry Landscape Recently, Bernstein analysts took a deep dive into the cruise industry, comparing two major players: Royal Caribbean (NYSE: RCL) and Carnival (NYSE: CCL). The analysts have awarded an Outperform rating to Royal Caribbean while assigning a Market-Perform rating to Carnival, based on recent assessments of the sector....

Continue Reading
NRG Energy's Impressive Q4 Performance and Exciting Future Plans

Updated Category News Views 498

NRG Energy Reports Strong Fourth Quarter Performance NRG Energy, Inc. (NYSE: NRG) has witnessed an uptick in its stock price following the announcement of its fourth-quarter results for 2024. Despite missing revenue expectations, the company demonstrated remarkable profitability. Revenue and Earnings Overview During the fourth quarter, NRG Energy reported revenues of...

Continue Reading
OpenText Introduces Cutting-Edge AI Platform for Enterprises

Updated Category News Views 317

Transforming Data Management with AI Technology OpenText has unveiled an exciting new platform that revolutionizes how enterprises manage their data. This next-generation AI Data Platform streamlines data management while incorporating innovative AI capabilities that empower organizations to activate their information securely. As the digital landscape continues to...

Continue Reading